Aevum Therapeutics is dedicated to the development of drugs treating neurodegenerative disorders. It has long been shown that exercise slows cognitive decline and reduces the risk for dementia along with many other health benefits. Thus, we strongly believe that harbors untapped potential for therapeutic discovery and are developing irisin, an exercise-induced peptide with strong neuroprotective effects, as our flagship therapeutic for the treatment of Alzheimer’s, Parkinson’s, and ALS.